CHMP5 and COVID-19: Recognizing the immune-evasive nature of XBB descendant lineages, both TAG-CO-VAC and VRBPAC recommended a mono-antigen composition for the 2023–2024 COVID-19 vaccine formulation, focusing on the Omicron XBB.1.5 subvariant spike protein [11,12].